期刊文献+

骨化三醇不同方案治疗血液透析继发甲状旁腺亢进疗效对比研究 被引量:1

下载PDF
导出
摘要 目的探讨骨化三醇不同方案治疗血液透析继发甲状腺亢进(SHPT)的临床疗效。方法选取慢性肾功能衰竭血液透析继发SHPT患者80例,随机分为常规组与冲击组,每组40例,两组在常规治疗基础上,常规组给予骨化三醇常规疗法,冲击组给予骨化三醇冲击疗法,均治疗8周,观察患者治疗前后血钙、血磷、甲状旁腺素(i PTH)、钙磷乘积变化及疗效。结果血钙、血磷、i PTH、钙磷乘积常规治疗前分别为(1.36±0.22)mmol/L、(2.15±0.12)mmol/L、(646.81±204.31)mmol/L、(2.95±0.56)mmol/L^2,治疗后分别为(1.61±0.14)mmol/L、(2.23±0.27)mmol/L、(498.25±205.34)mmol/L、(3.63±0.21)mmol/L^2,冲击组治疗前分别为(1.30±0.26)mmol/L、(2.17±0.10)mmol/L、(639.02±211.49)mmol/L、(2.87±0.62)mmol/L^2,治疗后分别为(1.86±0.35)mmol/L、(2.24±0.32)mmol/L、(345.81±128.74)mmol/L、(4.11±0.26)mmol/L^2,两组均治疗后较治疗前血钙与钙磷乘积升高、i PTH下降(P<0.05);治疗后血钙与钙磷乘积升高、i PTH下降幅度冲击组较常规组更为明显(P<0.05);冲击组治疗总有效率为95.00%高于常规组80.00%(P<0.05)。结论骨化三醇治疗慢性肾功能衰竭血液透析继发SHPT疗效较好,冲击疗法治疗效果优于常规疗法。
出处 《当代医学》 2017年第7期119-121,共3页 Contemporary Medicine
  • 相关文献

二级参考文献107

  • 1王成,娄探奇,唐骅,陈珠江,石成钢,尹培达,余学清.常用血液净化方法对维持性血液透析患者血清甲状旁腺素的清除效果[J].中华急诊医学杂志,2005,14(1):61-63. 被引量:108
  • 2<活性维生素D的合理应用>专家协作组.活性维生素D在慢性肾脏病继发性甲旁亢中合理应用的专家共识(修订版)[J].中华肾脏病杂志,2005,21(11):698-699. 被引量:97
  • 3王海燕.肾脏病学.3版.北京:人民卫生出版社,2008.
  • 4Locatel]i F,Martin-Mafo A,Hannedouche T,et a].Effect of membrane permeability on survival of hemodialysis patients[J].J Am Soc Nephro],2009,20(3). 645 654.
  • 5Natitmal Kidney Foundation. K/DOQ1 Clinical Practice Guidelines far Bone Metabolism and Disease in Chronic Kidney Disease[J]. Am J Kidney Dis, 2003, 42: S1-S202.
  • 6MATHEW S, I,UND RJ, CHAUDHARY LR, el al. Vitamin D) receptor activators can protect against vascular calcification[J]. J Am Soc Nephrol, 2008, 19: 1509-1519.
  • 7MIZOBUCHIM, FINCH JL, MARTIN DR, el al. Differential effects of vitamin D receptor activators on vascular eah,ificalion in uremic rats[J]. Kidney lnt, 2007, 72: 709-715.
  • 8ARDISSINO G, SCHMITT CP, TESTA S, et al. Calcitriol pulsetherapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. European Study Group on Vitamin D in Children with Renal failure[J]. Pediatr Nephrol, 2000, 14: 664-668.
  • 9MOE S, WAZNY LD, MARTIN JE. Oral calcitrinl versus oral alfaealcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: A randomized, crossover trial Ill. Can J Clin Pharmacnl, 2008, 15(1): e36-e43.
  • 10KRAIWIPORN KIATI'ISUNTHORN, KITTIKARN WUTYAM, ARTIT INDRANOI, et al. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyrnidism in haemodialysis patients [J]. Nephrology, 2011, 16: 277-284.

共引文献107

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部